Dotatoc

Dotatoc

Dotatoc is a somatostatin analogue peptide that is radiolabelled with emitters of beta minus particles, such as 90Y or 177Lu, and is used in the visualization and therapy of neuroendocrine tumors and their metastasis. It is also known as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotide.From: Essentials of In Vivo Biomedical Imaging [2019], Nuclear Medicine in Oncology [2018], Handbook of Nuclear Medicine and Molecular Imaging for Physicists [2022], Nuclear Medicine Physics [2019]

Optimization and Dose Reduction in Pediatric Medical Imaging

View Chapter

Purchase Book

Published in Lawrence T. Dauer, Bae P. Chu, Pat B. Zanzonico, Dose, Benefit, and Risk in Medical Imaging, 2018

Ted S. Treves, Briana Sexton-Stallone, Frederic H. Fahey

The role of PET/CT in the assessment of pediatric oncologic disorders has dramatically increased over the past few years. 18F-FDG PET has been found to be effective in the assessment of pediatric lymphoma and brain tumors, among other malignancies. 18F-FET (18F-fluoroethyl-L-tyrosine) and 18F-FLT (18F-Fluorothymidine) have been useful to assess response to therapy in brain tumors. 68Ga-DOTATOC and 68Ga-DOTATATE is very useful in the assessment of neuroblastoma and other neuroendocrine tumors. On-going radiopharmaceutical research and development are rapidly advancing and newer and more specific agents in the pipeline will likely improve the diagnostic sensitivity and specificity in several oncologic disorders.

Nuclear Medicine in Oncology

View Article

Journal Information

Published in Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization, 2018

Carla Oliveira, Rui Parafita, Ana Canudo, Joana Correia Castanheira, Durval C. Costa

Tumours with a high expression of somatostatin receptors are potential targets for treatment with somatostatin analogue peptides (DOTATOC or DOTATATE) radiolabelled with emitters of beta minus particles (90Y or 177Lu). This treatment, which enables the generally partial destruction of these tumours, is not a first-order option, but constitutes an alternative for plurimetastasised or inoperable tumours, when all other conventional strategies are exhausted. (Forrer et al. 2007; Zaknun et al. 2013).

Explore chapters and articles related to this topic

Optimization and Dose Reduction in Pediatric Medical Imaging

Nuclear Medicine in Oncology